跳转至内容
Merck
CN

1464001

USP

呋喃妥因

United States Pharmacopeia (USP) Reference Standard

别名:

N -(5-硝基-2-呋喃亚基)-1-氨基乙内酰脲, 呋喃坦啶, 硝基呋喃妥因

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C8H6N4O5
CAS号:
分子量:
238.16
Beilstein:
893207
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

nitrofurantoin

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1

InChI

1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+

InChI key

NXFQHRVNIOXGAQ-YCRREMRBSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

象形图

Health hazardExclamation mark

警示用语:

Danger

危险声明

危险分类

Acute Tox. 4 Oral - Resp. Sens. 1 - Skin Sens. 1

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

K A Boggess et al.
Obstetrical & gynecological survey, 51(6), 367-370 (1996-06-01)
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life-threatening pulmonary dysfunction. Symptoms include fever, chills, cough, pleuritic chest pain, dyspnea. Rarely, pleural effusion and/or pulmonary hemorrhage may occur. Diagnosis is made
Reappraisal of the risk/benefit of nitrofurantoin: review of toxicity and efficacy.
R R Shah et al.
Adverse drug reactions and acute poisoning reviews, 8(4), 183-201 (1989-01-01)
L A Paiva et al.
The American journal of gastroenterology, 87(7), 891-893 (1992-07-01)
Nitrofurantoin-induced hepatic injury has been established unequivocally as an entity by rechallenge experiences. We reviewed 12 previously reported cases in which rechallenge was described. The longest reported interval between initial injury and rechallenge-provoked injury was 4 yr. We report a
Guy Amit et al.
The Israel Medical Association journal : IMAJ, 4(3), 184-186 (2002-03-23)
Nitrofurantoin is a commonly prescribed urinary antiseptic. Hepatic injury has been associated with its use. To present three patients in whom long-term exposure to the drug resulted in chronic active hepatitis; and to review the epidemiology, clinical immunology, histopathology, pathogenetic
J E Gait
DICP : the annals of pharmacotherapy, 24(12), 1210-1213 (1990-12-01)
The prescribing information for nitrofurantoin states that patients with glucose-6-phosphate dehydrogenase deficiency may experience hemolysis following administration of the drug. Although there is no doubt that this statement is qualitatively correct, the degree of risk in the general population of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门